PDF | On Jun 23, , Jessica L Morris and others published FIGO’s updated recommendations for misoprostol used alone in gynecology and. In , the International Federation of Obstetrics and Gynecology (FIGO) produced a chart detailing recommended dosages of misoprostol. These dosage guidelines are produced by FIGO and WHO. Recommended doses of Misoprostol (Cytotec®) are provided in this site along with instructions for.

Author: Gugar Jular
Country: Suriname
Language: English (Spanish)
Genre: Medical
Published (Last): 11 June 2011
Pages: 382
PDF File Size: 9.33 Mb
ePub File Size: 14.46 Mb
ISBN: 510-3-90353-865-7
Downloads: 92925
Price: Free* [*Free Regsitration Required]
Uploader: Mogar

For fetal death in the third trimester see ‘Induction of Labour’ below. Jessica MorrisProject Manager What is postpartum haemorrhage? Project materials FIGO’s advocacy pack: Postpartum Haemorrhage PPH is the leading cause of maternal mortality in low-income countries.

Article on misprostol recommendations.

Conducted a review of the latest evidence which led to updating of the chart Conducted more than 40 expert panel sessions to disseminate the latest clinical information on PPH management Launched a survey with our member societies to find out more about the current status of country-level guidelines on PPH management FIGO’s member society survey In FIGO conducted a survey of our member societies, to find out about their national guidelines for PPH, and inclusion of key PPH medicines on essential medicines lists EMLs.

  ANETA JADOWSKA ZODZIEJ DUSZ PDF

Lancet, ; Sheldon et al. The correct dosage varies greatly according to gestation, indication and route of administration — using the correct dosage is vital for success and to prevent complications.

Instructions on preparing the oral solution misopeostol be found here. Pregnancy Termination a,b,1 1st Trimester. The most common cause of PPH is poor contraction of the uterus uterine atony. PPH leading to unnecessary deaths.

Postpartum Haemorrhage Initiative

Incomplete abortion a,2,3,4 1st Trimester. Misoprostol is a very powerful fiyo of uterine contractions in late pregnancy and can cause fetal death and uterine rupture if used in high doses.

A detailed document on this topic is available here Intrauterine fetal death f,g,1,5,6 wks: They are based on those originally produced by the Bellagio group in but updated regularly since. Jessica MorrisProject Manager. Induction of labour h,2,9. Give 2 doses and leave to work for weeks unless heavy bleeding or infection. If a higher dose than this is used, then uterine hyperstimulation with uterine rupture or fetal distress might be the result. Do not use if previous caesarean section.

A full pictorial guide on how to safely make up a ml batch of a 1 microgram per ml solution of misoprostol for oral administration can be found here. Gynuity have a wide range of useful resources available regarding misoprostol use which can be found here.

Dosage Guidelines – Misoprostol

Follow the dosage regimes carefully and do not exceed those doses. Missed abortion c,2 1st Trimester. Cervical ripening for surgical abortion a,d.

  ITALO CALVINO AMORES DIFICILES PDF

This independent site has been set up to distribute dosage guidelines for the use of misoprostol in obstetrics and gynaecology. Safe single doses of vaginal misoprostol for producing uterine contractions at various gestations. Exclude second twin before administration. Reduce doses in women with previous caesarean section.

Treatment of PPH with misoprostol, PPH treatment k,2,10 mcg sublingually single dose Where oxytocin is not available misoprostl storage conditions are inadequate.

Where oxytocin is not available or storage conditions are inadequate. Induction of labour h,2,9 25mcg vaginally 6-hrly or 25mcg orally 2-hrly Do not use if previous caesarean section. Intrauterine fetal death f,g,1,5,6. Download the above chart in PDF format click here. A detailed description of the treatment can also be found here Cervical ripening for surgical misoprostll a,d weeks: The aim of the survey was also to establish any challenges to implementing evidence-based practice, in order to further support FIGO Member Associations in working towards their maternal health goals.